The pharmaceutical world is observing a major shift in diabetes therapy with the emergence of GLP-1 transdermal devices. These devices offer a seemingly more user-friendly alternative to injections of GLP-1 receptor agonists, minimizing the frequency of daily needle pokes. The innovation administ